UPDATE: Citi Reiterates Buy on Bristol-Myers Squibb
Citi reiterates a Buy rating on Bristol-Myers Squibb (NYSE: BMY) and a price target of $40.
Citi notes, “We model ‘15E-‘20E EPS growth for BMY of ~16% supported by added risk-adj sales for BMY's anti-PD-1 antibody in oncology & our maintained risk-adj. sales est's. for, BMY's hepatitis C franchise & best- in-class blood thinner Eliquis. Our PT is supported by a DCF value of $44/share.”
Bristol-Myers Squibb closed at $34.74 on Wednesday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.